Octapharma licenses new BAC purification ligand

By Gareth Macdonald

- Last updated on GMT

Related tags Protein Antibody

Bioprocess purification chromatography tech wins BAC new deal after Swiss protein maker Octapharma licenses it for commercial-scale manufacture.

The technology in question, CaptureSelect, uses camelid-derived single domain antibody fragments to produce affinity ligands capable of capturing specific proteins during biomanufacturing.

BAC claims the ligands offer increased stability and broad antigen-specific binding compared to traditional affinity purification methods.

Under the new agreement, Lachen-headquartered Octapharma will use a CaptureSelect affinity ligand it developed in collaboration with BAC to purify recombinant human granulocyte-colony stimulating factor (G-CSF).

Octapharm, which intends to make G-CSF for oncology applications, has already used BAC’s platform to develop purification processes for the production of its recombinant factor IX drug and for its candidate factor VIII.

In a press statement Laurens Sierkstra, BAC CEO, said the deal “confirms the reliability of the CaptureSelect platform to consistently produce highly specific affinity ligands for the purification of any protein​.”

And while this is the standard comment when any technology firm agrees a new license, in this case it is supported by CaptureSelect’s track-record of winning BAC repeat business.

In April, for example, France’s LFB Biotechnologies licensed a new affinity ligand for the large scale production of Factor VIIa (rhFVIIa), expanding on the deal it signed in 2008​.

And, prior to that in February, GE Healthcare also expanded its deal with BAC, licensing an affinity resin for the purification of alpha-1 antitrypsin (AAT) from blood plasma that was developed using the CaptureSelect platform.

That deal built on a partnership​ formed in 2006 which, in 2008, saw CaptureSelect ligand’s supplied to Kirin Pharma’s subsidiary Hematech for the production of human antibodies in transgenic cows.

Related news

Related products

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

State-of-the-Art Virtual Pharma Factory Tour

State-of-the-Art Virtual Pharma Factory Tour

Content provided by METTLER TOLEDO | 09-Jun-2023 | Event Programme

Join METTLER TOLEDO’s weighing experts on a virtual tour of a state-of-the-art manufacturing facility. On the call, you'll be digitally transported...